Participate in the ReGen-Brain Clinical Trial to Regenerate the Alzheimer’s Brain
ReGen-Brain is a Phase 2 clinical trial of allopregnanolone (ALLO) to evaluate its effectiveness as a therapeutic to regenerate brain structure and function in people with mild Alzheimer's disease.
ALLO is a naturally occurring molecule in the human body and brain which has proven to be safe in persons with Alzheimer’s disease.
*Allopregnanolone is an “Experimental/Investigational drug” which means that the U.S. Food and Drug Administration (FDA) has not approved allopregnanolone for the treatment of Alzheimer’s disease beyond its use in this clinical trial.
Your participation in this study will advance development of allopregnanolone (ALLO) for Alzheimer’s disease. You will also be helping others who have a similar medical problem in the future by contributing to medical research.
